• Users Online: 181
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2019  |  Volume : 9  |  Issue : 4  |  Page : 216-223

Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?


1 Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica; Illinois Eye and Ear Infirmary, University of Illinois, Chicago, Illinois, USA
2 Department of Ophthalmology, Bascom Palmer Eye Insitute, Miami, FL, USA
3 Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica
4 Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica; College of Engineering, Cornell University, Ithaca, NY, USA

Correspondence Address:
Dr. Lihteh Wu
Macula, Vitreous, Retina Associates of Costa Rica, First Floor, Mercedes Tower, Paseo Colon, San Jose

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/tjo.tjo_67_19

Rights and Permissions

Prior to the development of panretinal photocoagulation (PRP) in the 1970s, proliferative diabetic retinopathy (PDR) was the most common cause of blindness in diabetic patients. The diabetic retinopathy study demonstrated that PRP could decrease severe visual loss from PDR by 50%. Since then and for the past four decades, PRP has been the treatment of choice for eyes with PDR. In the past decade, vascular endothelial growth factor (VEGF) inhibition has become the treatment of choice for diabetic macular edema (DME). When treated intensively with anti-VEGF drugs, about one-third of eyes with DME experience an improvement in their diabetic retinopathy severity scale. Randomized clinical trials comparing ranibizumab to PRP and aflibercept to PRP have shown that VEGF inhibitors cause regression of intraocular neovascularization but need to be given on a fairly regular basis. Despite these promising results, concerns about treatment adherence have surfaced. Patients with PDR that are treated solely with anti-VEGF drugs and somehow interrupt their treatment are at a high risk of developing irreversible blindness. Combination treatment of PRP plus an anti-VEGF drug may be the treatment of choice for PDR.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1152    
    Printed66    
    Emailed0    
    PDF Downloaded219    
    Comments [Add]    

Recommend this journal